INDEX

A
AB1010, 1127
Abdominal neoplasia, MRI of, 1066
Active controls, defined, 1053
Acute systemic inflammatory reaction, bisphosphonates and, 1097
Adaptive radiotherapy, 1158–1159
Adaptive trial designs, defined, 1053
AKC-CHF. See American Kennel Club–Canine Health Foundation (AKC-CHF).
American College of Veterinary Internal Medicine, 1028
American College of Veterinary Radiology, 1028
American Kennel Club–Canine Health Foundation (AKC-CHF), 1026
Aminobisphosphonate(s), in cancer-bearing dogs and cats, 1102–1105
Animal Medical Center, DNA vaccine program for melanoma at, 1115
Antiangiogenesis, bisphosphonates and, 1099–1100
Antibody(ies)
immunotoxin-conjugated, 1144
monoclonal, unconjugated, 1143–1144
radionuclide-conjugated, 1144–1145
Anticancer vaccines, 1111–1119
goal for, 1113
types of, 1113–1115
Antigen(s), cancer testes, 1113–1115
Autophosphorylation, 1121
Avoidance, conformal. See Conformal avoidance.

B
Bacillus of Calmette and Guérin and mycobacterial cell wall–DNA complex, 1138–1139
Bayesian adaptive designs, for clinical trials, 1047–1048
Bayesian approach to statistical analysis, defined, 1053
Biologic response modifiers, 1138–1141
Bacillus of Calmette and Guérin and mycobacterial cell wall–DNA complex, 1138–1139
liposome-DNA complexes, 1139–1140
liposome-encapsulated muramyl tripeptide, 1139
oncolytic viruses, 1140–1141
Bisphosphonate(s)
absorption of, 1093–1094
adverse effects of, 1096–1098
antiresorptive potency of, 1092–1093
chemical structure of, 1092–1093
described, 1091–1092
distribution of, 1094–1095
excretion of, 1095
in cancer management, 1091–1100
antiangiogenesis, 1099–1100
anti-invasive effects, 1099
antiproliferative effects, 1099
molecular targets, 1098–1100
therapeutic response assessment, 1100–1102
bone-specific biochemical methodologies, 1101–1102
newer radiologic methods, 1100–1101
traditional radiologic methods, 1100
mechanism of action of, 1095–1096
metabolism of, 1095
pharmacokinetics of, 1093–1095
terminal elimination of, 1095
Bone pain, osteolytic, aminobisphosphonates in, 1102–1104
B-RAF, 1126
Brain tumors
CT of, 1061–1063
MRI of, 1065–1066

Note: Page numbers of article titles are in boldface type.
Cancer
clinical trials for
basic structure of, 1033, 1034
development and implementation of, 1033–1057. See also Clinical trials.
head and neck, conformal avoidance and, 1154–1155
immunotherapy for, 1137–1149. See also Immunotherapy.
in dogs, problems associated with, 1023–1024
management of, bisphosphonates in, 1091–1110. See also Bisphosphonate(s).
vaccines against, 1113–1117. See also Anticancer vaccines.
Cancer immunosurveillance, 1112
Cancer patients, advanced imaging for, 1059–1077. See also specific modality, e.g., Computed tomography (CT).
cross-sectional imaging modalities, 1060–1067
CT, 1060–1064
MRI, 1065–1067
PET, 1067–1073
PET/CT, 1067–1073
PET/CT fusion, 1069–1070
Cancer testes antigens, 1113–1115
Canine Genome Project, 1025
Cat(s), cancer in, aminobisphosphonates in, 1102–1105
CCOGC. See Comparative Oncology and Genomics Consortium (CCOGC).
Chemotherapy, 1079–1090
clinical trials, 1085–1087
combination therapy, 1085
dosing, 1080
metronomic, 1079
as antiangiogenic strategy, 1082–1085
circulating endothelial progenitor cells, 1083–1084
described, 1082–1083
growth/survival factor modulation, 1084–1085
selective endothelial cell cytotoxicity, 1083
pharmacology of, 1081–1082
Circulating endothelial progenitor cells, in metronomic chemotherapy, 1083–1084
Clinical trials
adaptive designs, 1047
basic structure of, 1033, 1034
Bayesian adaptive designs, 1047–1048
cancer-related, development and implementation of, 1033–1057
chemotherapy-related, 1085–1087
crossover trials, 1051–1052
enrichment, 1050–1051
informed consent for, 1052
noninferiority trials, 1051
phase 0, defined, 1054
phase combinations, 1049–1050
phase I, 1035–1038
candidates for, 1036
defined, 1054
described, 1035–1036
dose escalation strategies, 1036–1038
starting dose in, setting of, 1036
phase II, 1038–1043
controlled, 1041–1043
defined, 1054
described, 1038–1040
end points of activity/efficacy, 1040–1041
phase III, 1043–1044
defined, 1054
phase IV, 1044
defined, 1054
phase 0, 1045–1046
randomization in, 1044–1045
randomized discontinuation trials, 1048–1049
standard designs for, modifications/alternatives to, 1044–1052
stopping rules in, 1047
terminology related to, 1053–1055
traditional drug development flow in, 1035–1044
Cohort study, defined, 1053
Communication
with oncology clients, 1013–1022
breaking news/presenting diagnosis, 1015–1016
end-of-life decisions, 1019–1020
euthanasia, 1020–1021
offering options, 1016–1018
providing support, 1018–1019
responding to client emotion, 1016
Communication skills, review of, 1013–1015
Comparative oncology, 1023–1032
cancer in dogs and, 1024–1029
Comparative Oncology and Genomics Consortium (CCOGC), 1028
Comparative Oncology Program (COP), 1028
Comparative Oncology Trials Consortium (COTC), 1028
Computed tomography (CT), for cancer patients, 1060–1064
  clinical applications, 1061–1064
  brain tumors, 1061–1063
  extremity-related neoplasia, 1064
  integumental neoplasia, 1064
  intra-abdominal neoplasia, 1064
  intrathoracic neoplasia, 1063–1064
  mediastinal tumors, 1064
  metastatic lung disease, 1064
  nasal tumors, 1063
  non–CNS head and neck tumors, 1063
  oral cavity tumors, 1063
  primary lung tumors, 1063–1064
  skull tumors, 1063
  spinal/paraspinal tumors, 1061–1063
  technical advances in, 1060–1061
Conditional power, defined, 1053
Conformal avoidance
  described, 1153–1154
  helical tomotherapy and, 1159
  human head and neck cancer and, 1154–1155
  IMRT and, 1152–1153
Control(s), active, defined, 1053
COP. See Comparative Oncology Program (COP).
COTC. See Comparative Oncology Trials Consortium (COTC).
Crossover trials, 1051–1052
Cross-sectional imaging modalities, for cancer patients, 1060–1067
CT. See Computed tomography (CT).
Cytokine therapy, 1141–1143
  IL-2, 1141–1142
  IL-12, 1142
  tumor necrosis factor-α, 1142–1143
Cytoplasmic kinases, 1122
DNA vaccine program, for melanoma, at Animal Medical Center, 1115
Dog(s), cancer in
  aminobisphosphonates in, 1102–1105
  comparative oncology and, 1024–1029
  problems associated with, 1023–1024
EGFR, 1127
Electrolyte(s), abnormalities of, bisphosphonates and, 1098
End-of-life decisions, communicating with oncology clients about, 1019–1020
Enrichment, defined, 1053
Enrichment clinical trials, 1050–1051
Euthanasia, communicating with oncology client about, 1020–1021
Extremity(ies), neoplasia of
  CT of, 1064
  MRI of, 1066–1067
Eye(s), bisphosphonates effects on, 1097
First-in-species trial, defined, 1053
Frequentist approach to statistical analysis, defined, 1053
Futility analysis, defined, 1053
Gastrointestinal tract, bisphosphonates effects on, 1096
Gefitinib, 1125–1126
Gleevec, 1123–1125, 1127–1128
Growth/survival factor modulation, in metronomic chemotherapy, 1084–1085
Head and neck cancer, human, conformal avoidance and, 1154–1155
Head and neck tumors, non–CNS
  CT of, 1063
  MRI of, 1066
Heat shock protein 90 (HSP90) inhibitors, 1128–1129
Helical tomotherapy, 1151–1165
  biologic advantages to, 1159–1161
  conformal avoidance and, 1159
  image-guided radiation therapy and, 1155–1157
  negative implications of, 1161–1162
Histone deacetylase inhibitors, 1131–1132
HSP90 inhibitors. See Heat shock protein 90 (HSP90) inhibitors.
Hypercalcemia, tumor-induced, management of, aminobisphosphonates in, 1104–1105
Hypothesis(es), null, defined, 1054
IL. See Interleukin(s).
Image-guided radiation therapy, helical tomotherapy and, 1155–1157
Imaging, advanced, for cancer patients, 1059–1077. See also specific modality and Cancer patients, advanced imaging for.
Immune responses, described, 1112
Immunity, defined, 1111
Immunology, tumor-related, 1111–1113
Immunosurveillance, cancer, 1112
Immunotherapy, 1137–1149
future challenges for, 1145–1146
nonspecific tumor, 1113, 1137–1143
biologic response modifiers, 1138–1141
Bacillus of Calmette and Guérin and mycobacterial cell wall–DNA complex, 1138–1139
liposome-DNA complexes, 1139–1140
liposome-encapsulated muramyl tripeptide, 1139
oncolytic viruses, 1140–1141
cytokine therapy, 1141–1143
IL-2, 1141–1142
IL-12, 1142
tumor necrosis factor-α, 1142–1143
tumor-specific, 1143–1145
immunotoxin-conjugated antibodies, 1144
radionuclide-conjugated antibodies, 1144–1145
unconjugated monoclonal antibodies, 1143–1144
Immunotoxin-conjugated antibodies, 1144
IMRT. See Intensity-modulated radiation therapy (IMRT).
Integument, neoplasia of
CT of, 1064
MRI of, 1066–1067
Intensity-modulated radiation therapy (IMRT), 1151–1165
conformal avoidance and, 1152–1153
negative implications of, 1161–1162
Intention-to-treat analysis, defined, 1054
Interleukin(s)
IL-2, 1141–1142
IL-12, 1142
Interviewing techniques, examples of, 1014
Intra-abdominal neoplasia, CT of, 1064
Intrathoracic neoplasia, CT of, 1064
K
Kinase(s)
cytoplasmic, 1122
protein, 1121–1122
dysfunction of, 1123
tyrosine, 1122
Kinase inhibitors, 1126–1128
human experience with, 1121–1126
Kit, 1126–1127
L
Liposome-DNA complexes, 1139–1140
Liposome-encapsulated muramyl tripeptide, 1139
Lung disease, metastatic, CT of, 1064
Lung tumors, primary, CT of, 1063–1064
M
MAF. See Morris Animal Foundation (MAF).
Magnetic resonance imaging (MRI), for cancer patients, 1065–1067
clinical applications
abdominal neoplasia, 1066
brain tumors, 1065–1066
extremity-related neoplasia, 1066–1067
non–CNS head and neck tumors, 1066
clinical applications of, 1065–1067
MRI of, integumental neoplasia, 1066–1067
technical advances in, 1065
Mandible, osteonecrosis of, bisphosphonates and, 1098
Maxilla, osteonecrosis of, bisphosphonates and, 1098
Maximum tolerated dose (MTD), 1080
Mediastinal tumors, CT of, 1064
Melanoma, DNA vaccine program for, at Animal Medical Center, 1115
Memorial Sloan-Kettering Cancer Center, 1115
Met, 1127
Metastatic lung disease, CT of, 1064
Monoclonal antibodies, unconjugated, 1143–1144
Morris Animal Foundation (MAF), 1026
MRI. See Magnetic resonance imaging (MRI).
MTD. See Maximum tolerated dose (MTD).
N
Nasal tumors, CT of, 1063
National Cancer Institute, 1028
Neck cancer, human, conformal avoidance and, 1154–1155
INDEX

Neck tumors, non–CNS
  CT of, 1063
  MRI of, 1066
Nephrotic syndrome, bisphosphonates and,
  1097–1098
Noninferiority trials, 1051
Nonspecific tumor immunotherapy,
  1137–1143. See also Immunotherapy,
  nonspecific tumor.
Null hypothesis, defined, 1054
Oncolytic viruses, 1140–1141
Oral cavity, tumors of, CT of, 1063
Osteolytic bone pain, aminobisphosphonates
  in, 1102–1104
Osteonecrosis, of maxilla and mandible,
  bisphosphonates and, 1098
Paraspinal tumors
  CT of, 1061–1063
  MRI of, 1065–1066
PET. See Positron emission tomography (PET).
PET/CT. See Positron emission tomography (PET)/CT.
Phase 0 trials, 1045–1046
  defined, 1054
Phase I trials, 1035–1038
  defined, 1054
Phase II trials, 1038–1043
  defined, 1054
Phase III trials, 1043–1044
  defined, 1054
Phase IV trials, 1044
  defined, 1054
Phosphatidyl inositol 3 kinase (PI3K), 1122
PI3K. See Phosphatidylinositol 3 kinase (PI3K).
Positron emission tomography (PET)
  for cancer patients, 1067–1073
    clinical applications, 1071–1073
    image interpretation, 1070–1071
    practical aspects, 1070
    technical aspects, 1067–1071
  physics of, 1067–1069
Positron emission tomography (PET)/CT, for cancer patients, 1067–1073
  clinical applications, 1071–1073
  image interpretation, 1070–1071
  practical aspects, 1070
  technical aspects, 1067–1071
Positron emission tomography (PET)/CT
  fusion, for cancer patients, 1069–1070
Positron-emitting radiopharmaceutic agents,
  physics of, 1067–1069
Power, conditional, defined, 1053
Predictive factors, defined, 1054
Prognostic factors, defined, 1054
Prospective clinical trials, defined, 1054
Proteasome inhibitors, 1129–1131
Protein kinases, 1121–1122
  dysfunction of, 1123
Radiation therapy
  adaptive, 1158–1159
  image-guided, helical tomotherapy and,
    1155–1157
  intensity-modulated, 1151–1165. See also
    Intensity-modulated radiation therapy (IMRT).
    three-dimensional conformal,
    1151–1152
Radionuclide-conjugated antibodies,
  1144–1145
Randomization
  defined, 1054
  in clinical trials, 1044–1045
  unbalanced, defined, 1055
Randomized discontinuation trials,
  1048–1049
RAS-RAF-MEK-ERK/p38/JNK families, 1122
Receptor tyrosine kinases (RTKs), 1122
Renal failure, acute and chronic,
  bisphosphonates and, 1097
Retrospective studies, defined, 1054
RTKs. See Receptor tyrosine kinases (RTKs).
Selective endothelial cell cytotoxicity, in
  metronomic chemotherapy, 1083
Skull tumors, CT of, 1063
Small molecule inhibitors
  AB1010, 1127
  EGFR, 1127
  gefitinib, 1125–1126
  Gleevec, 1123–1125, 1127–1128
  histone deacetylase inhibitors,
    1131–1132
  HSP90 inhibitors, 1128–1129
  kinase inhibitors, human experience
    with, 1121–1126
  Kit, 1126–1127
  Met, 1127
  proteasome inhibitors, 1129–1131
  role of, 1121–1136
Small (continued)
  SU11654, 1127
  SUTENT, 1125

Spinal/paraspinal tumors
  CT of, 1061–1063
  MRI of, 1065–1066

Standard of care, defined, 1054

Statistical analysis
  Bayesian approach to, defined, 1053
  frequentist approach to, defined, 1053

Stopping rules
  defined, 1054
  in clinical trials, 1047

Stratification, defined, 1054

SU11654, 1127
SUTENT, 1125

T

Three-dimensional conformal radiation therapy, 1151–1152

Tomotherapy, helical, 1151–1165. See also Helical tomotherapy.

Tumor(s)
  brain
    CT of, 1061–1063
    MRI of, 1065–1066
  head and neck, non–CNS
    CT of, 1063
    MRI of, 1066
  hypercalcemia due to, management of, aminobisphosphonates in,
    1104–1105
  immunology of, 1111–1113
  immunotherapy for, nonspecific, 1113
  lung, primary
    CT of, 1063–1064
  mediastinal, CT of, 1064
  nasal, CT of, 1063
  oral cavity, CT of, 1063
  skull, CT of, 1063
  spinal/paraspinal
    CT of, 1061–1063
    MRI of, 1065–1066

Tumor necrosis factor-α, 1142–1143

Tumor-specific immunotherapy, 1143–1145. See also Immunotherapy, tumor-specific.

Type I error, defined, 1054

Type II error, defined, 1054

Tyrosine kinases, 1122

Unbalanced randomization, defined, 1055

Unconjugated monoclonal antibodies, 1143–1144

V

Vaccine(s), anticancer, 1111–1119. See also Anticancer vaccines.

VCOG. See Veterinary Co-Operative Oncology Group (VCOG).

VCOG-CTCAE. See Veterinary Cooperative Oncology Group Common Terminology Criteria for Adverse Events (VCOG-CTCAE).

VCS. See Veterinary Cancer Society (VCS).

Veterinary Cancer Society (VCS), 1028

Veterinary Co-Operative Oncology Group (VCOG), 1028

Veterinary Cooperative Oncology Group Common Terminology Criteria for Adverse Events (VCOG-CTCAE), 1037

Virus(es), oncolytic, 1140–1141